Implicity has raised $40 million, about 35 million euros, in growth equity led by IRIS and Five Arrows, the alternative assets arm of Rothschild & Co. The round was announced September 9. It follows a $23 million Series A in 2022 and takes the total to roughly $63 million.
The platform pulls data off cardiac implants from different manufacturers, normalizes it, and pushes alerts into the EHR. Implicity says it covers more than 250 medical centers and 120,000 patients a day across the US, France and Germany. Two algorithms carry FDA clearance as Class II software. The ILR ECG Analyzer was cleared in 2021 and again in 2025, that time for Abbott, Biotronik, Boston Scientific and Medtronic devices. SignalHF, which scores heart failure risk, was cleared in 2023.
A 2025 Heart Rhythm paper (Varma et al., 22(10):2661-2668) reported 26 percent lower mortality among ICD patients monitored on the system than on conventional remote monitoring. Mortality data is rare for monitoring software, and it is what separates this round from the usual digital health raise. Implicity was founded in Paris in 2016 by electrophysiologist Arnaud Rosier and has run US operations from Cambridge, Massachusetts since 2022.